Testosterone replacement therapy may benefit male cancer survivors with testosterone deficiency

A new study has found that many male cancer survivors who develop testosterone deficiency after receiving chemotherapy or radiation therapy have an impaired quality of life and reduced energy levels. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study suggests that young male cancer survivors with testosterone deficiency may benefit from testosterone replacement therapy.

Testosterone deficiency is a late side effect of radiation therapy and chemotherapy that occurs in approximately 15 percent of male cancer survivors. Investigators led by Professor Richard Ross, MD, FRCP, of the University of Sheffield in the United Kingdom examined the relationship between testosterone levels, quality of life, self-esteem, fatigue and sexual function in 176 young male cancer survivors compared with 213 young men without cancer.

Young male cancer survivors said they experienced a marked impairment in quality of life, as well as reduced energy levels and quality of sexual function. These experiences were exacerbated in survivors with testosterone deficiency. Psychological distress was not elevated, self-esteem was normal, and sexual relationships were not impaired in male cancer survivors, however.

Professor Ross commented: "This is an important study demonstrating that low testosterone levels are common in male cancer survivors and associated with an impaired quality of life. However, the relationship between testosterone levels and quality of life is complex and appears to depend on a threshold level rather than on a direct correlation. We now need interventional trials with testosterone to determine which young male cancer survivors will benefit from replacement therapy."

Article: "Quality of life, self-esteem, fatigue and sexual function in young men after cancer: a controlled cross-sectional study." Diana M. Greenfield, Stephen J. Walters, Robert E. Coleman, Barry W. Hancock, John A. Snowden, Stephen M. Shalet, Leonard R. DeRogatis, Richard J.M. Ross. Cancer; Published Online: February 22, 2010 (DOI: 10.1002/cncr.24898).

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-powered tool predicts gene activity in cancer cells from biopsy images